madman
Super Moderator
Purpose: We aimed to investigate the effect of continuous positive airway pressure (CPAP) administered for the treatment of obstructive upper airway on lower urinary tract symptoms and erectile dysfunction in male patients.
Materials and Methods: A total of 626 males with suspected obstructive sleep apnea syndrome (OSAS) were evaluated prospectively. Nocturnal polysomnography tests were administered to the male. After the application of the exclusion criteria, 54 patients with severe OSAS (Apnea-Hypopnea Index ≥30) were included in the study. International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF-15), and nocturia were assessed in all patients before and after CPAP therapy, and prostate volume, total prostate-specific antigen (tPSA), and uroflowmetric measurements were assessed in patients aged >40 years.
Results: The mean age of the 54 patients was 47.06±11.15 years. Post-treatment IIEF scores were better than pre-treatment scores (24.27±7.58 vs. 22.68±8.65, p=0.014). IPSS values, nocturia, and uroflowmetric outcomes significantly improved after CPAP therapy (p<0.05). On the other hand, the mean values of body mass index, tPSA, prostate volume, and postvoid residual urine volume did not differ significantly after treatment.
Conclusions: CPAP therapy improves lower urinary tract symptoms, nocturia, and erectile dysfunction in males with severe OSAS.
CONCLUSIONS
The results of the current study indicate that CPAP therapy provides benefits to patients with severe OSAS in terms of improvement of LUTS, nocturia, and ED. Therefore, patients presenting to the urology clinic with complaints of LUTS and ED should be questioned about OSAS. Moreover, those presenting to a neurology clinic with complaints of OSAS should be asked about LUTS and ED. Better-designed studies with a larger sample size are needed to verify and support our findings.
Materials and Methods: A total of 626 males with suspected obstructive sleep apnea syndrome (OSAS) were evaluated prospectively. Nocturnal polysomnography tests were administered to the male. After the application of the exclusion criteria, 54 patients with severe OSAS (Apnea-Hypopnea Index ≥30) were included in the study. International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF-15), and nocturia were assessed in all patients before and after CPAP therapy, and prostate volume, total prostate-specific antigen (tPSA), and uroflowmetric measurements were assessed in patients aged >40 years.
Results: The mean age of the 54 patients was 47.06±11.15 years. Post-treatment IIEF scores were better than pre-treatment scores (24.27±7.58 vs. 22.68±8.65, p=0.014). IPSS values, nocturia, and uroflowmetric outcomes significantly improved after CPAP therapy (p<0.05). On the other hand, the mean values of body mass index, tPSA, prostate volume, and postvoid residual urine volume did not differ significantly after treatment.
Conclusions: CPAP therapy improves lower urinary tract symptoms, nocturia, and erectile dysfunction in males with severe OSAS.
CONCLUSIONS
The results of the current study indicate that CPAP therapy provides benefits to patients with severe OSAS in terms of improvement of LUTS, nocturia, and ED. Therefore, patients presenting to the urology clinic with complaints of LUTS and ED should be questioned about OSAS. Moreover, those presenting to a neurology clinic with complaints of OSAS should be asked about LUTS and ED. Better-designed studies with a larger sample size are needed to verify and support our findings.
